CD34 and acute myeloid leukemia: In the examination of clinical cases, we frequently observe a hypocellular marrow (5–10% of cellularity) from AML patients at Day14 post-chemotherapy, with no or rare blasts detected by CD34 immunostaining, manual counting and/or flow cytometric analysis.